Although Dr Moskowitz said: “This rapid mobilization of major medical centers across the United States reflectsthe urgent need to treat the very large numbers of people in hospital intensive care units sufferingwith COVID-19 ARDS and requiring ventilation. We expect quick enrollment in this trial to determinewhether remestemcel-L can reduce mortality in these patients.”
These people don't know what "quick" is.
Approval to trial 5 April
Trial announced 8 April
Ann increase to 300 patients 29 April
First patients dosed 5 May
I've lost the excitement that this will get a "quick" result.
Ann: First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS, page-21
-
- There are more pages in this discussion • 168 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.25 |
Change
-0.053(4.02%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $16.47M | 13.35M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 86330 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 91990 | 8 |
View Market Depth
| Last trade - 14.07pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |